Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions: PF-04950615 (RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Chula Vista, California • Miami, Florida • Overland Park, Kansas + 4 more

Conditions: Nonfamilial Hypercholesterolemia, Physical Inactivity
Interventions: Rosuvastatin, Exercise Training; Drug · Behavioral
Lead sponsor: Purdue University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: HIV Infections, Healthy, Hyperlipidemia, Lipodystrophy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperlipidemia
Interventions: Chewable plant sterol; Dietary Supplement
Lead sponsor: Piper Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Altos, California

Conditions: Alzheimer's Disease, Oxidative Stress, Dementia, Hyperlipidemia, Inflammation
Interventions: Fish Oil, Lipoic Acid, Fish Oil Placebo, Lipoic Acid Placebo; Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 55 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hyperlipidemia
Interventions: MCT oil + Butter in Coffee; Dietary Supplement
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions: Sirolimus; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 13 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
Interventions: telephone counseling; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 40 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections, Lipodystrophy
Interventions: Pravastatin sodium, Fenofibrate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 57
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more

Conditions: Diabetes Mellitus, Coronary Artery Disease, Osteoporosis, Hypertension, Hyperlipidemia
Interventions: Computerized Reminders Medications Monitoring, Computerized Test Results Management Application, Computerized Reminders Hypertension Management, Computerized Reminders Osteoporosis Screening and Mgt; Behavioral
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperlipidemia, Hypertension
Interventions: HeartBeet Clinic, Self-paced education; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment; Drug
Lead sponsor: Takeda; Industry
Eligibility: 8 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Chronic Disease, Hypertension, Hyperlipidemia, Diabetes Mellitus, Osteoarthritis, COPD, Cardiovascular Disease
Interventions: Patient Primer Tool; Behavioral
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypercholesterolemia
Interventions: BMS-201038 (AEGR-733), Ezetimibe; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Hyperlipidemia
Interventions: Capros dietary supplement; Dietary Supplement
Lead sponsor: Chandan K Sen; Other
Eligibility: 21 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Interventions: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 149
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 131 more

Conditions: Familial Hypercholesterolemia
Interventions: atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 6 Years to 15 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 3 more

Conditions: Hypercholesterolaemia
Interventions: laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3, laroprovstat/rosuvastatin 4, Placebo to match laroprovstat/rosuvastatin 1,2,3, Placebo to match laroprovstat/rosuvastatin 4, Rosuvastatin 1, Rosuvastatin 2, Rosuvastatin 3, Rosuvastatin 4, Placebo to match Rosuvastatin; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 26
States / cities: Sun City West, Arizona • Gardena, California • Lomita, California + 22 more

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Hypertension, Arthritis, Coronary Artery Disease, Hepatitis, Diabetes, Asthma, Hyperlipidemia, HIV
Interventions: HARP Intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hyperlipidemia, Elevated Lp(a)
Interventions: 2-HOBA (Hobamine); Dietary Supplement
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Hypertriglyceridemia
Interventions: Simvastatin, acetylsalicylic acid (ASA), omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Mipomersen, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Jupiter, Florida • Winter Park, Florida • Atlanta, Georgia + 6 more

Conditions: Obesity, Depression, Diabetes, Hypertension, Hypercholesterolemia
Interventions: Holistic health; Behavioral
Lead sponsor: Duke Clergy Health Initiative; Other
Eligibility: 18 Years and older
Enrollment: 1,114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?

Metabolism and Body Shape of Healthy Children and Children With Chronic Infections

Impact of a Chewable Plant Sterol Supplement on LDL-C in A Real-World Setting

Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease

Effect of Butter & MCT Oil on Lipoproteins - A RCT

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

Improving Medication Adherence in Comorbid Conditions

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

Improving Quality With Outpatient Decision Support

HeartBeet Clinic Pilot Trial

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

A Pilot Study to Improve Patient-Doctor Communication

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Atorvastatin Three Year Pediatric Study

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

Open Label Study of Long Term Evaluation Against LDL-C Trial

The Health Access and Recovery Peer Program

2-HOBA Supplementation in People With Elevated Lipoprotein(a)

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Study of a Holistic Health Program for United Methodist Clergy